Zura Bio Q3 net loss widens on higher R&D costs
ZURA•Zura Bio's third-quarter net loss widened to $25.83 million, or $0.20 per share, as research and development costs rose. The company ended the quarter with $187.7 million in cash and expects its runway to extend through at least the end of 2028.
1. Quarterly results
Zura Bio reported a third-quarter net loss of $25.83 million, or $0.20 per share. Operating expenses were $28.77 million, including higher research and development costs tied to Phase 2 tibulizumab studies and the start-up of the NEXUS-PMR study; general and administrative expenses also rose on higher professional fees.
2. Cash and trial updates
The company ended the quarter with $187.7 million in cash and expects it to fund operations through at least the end of 2028. It completed enrollment for Phase 2 tibulizumab studies in hidradenitis suppurativa and systemic sclerosis, exceeding targets. Zura Bio expects TibuSHIELD topline data in hidradenitis suppurativa in the fourth quarter of 2026 and TibuSURE topline data in systemic sclerosis in the first half of 2027.
